NZ508059A - Use of APO B secretion/MTP inhibitors to reduce intestinal fat absorption - Google Patents
Use of APO B secretion/MTP inhibitors to reduce intestinal fat absorptionInfo
- Publication number
- NZ508059A NZ508059A NZ508059A NZ50805900A NZ508059A NZ 508059 A NZ508059 A NZ 508059A NZ 508059 A NZ508059 A NZ 508059A NZ 50805900 A NZ50805900 A NZ 50805900A NZ 508059 A NZ508059 A NZ 508059A
- Authority
- NZ
- New Zealand
- Prior art keywords
- secretion
- pharmaceutically acceptable
- acceptable salts
- trigyceride
- microsomal
- Prior art date
Links
- 230000028327 secretion Effects 0.000 title abstract 4
- 230000000968 intestinal effect Effects 0.000 title abstract 3
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 101710095342 Apolipoprotein B Proteins 0.000 abstract 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 3
- 230000003228 microsomal effect Effects 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229940121649 protein inhibitor Drugs 0.000 abstract 3
- 239000012268 protein inhibitor Substances 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 239000005864 Sulphur Chemical group 0.000 abstract 2
- 239000000883 anti-obesity agent Substances 0.000 abstract 2
- 229940125710 antiobesity agent Drugs 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- ZSOZYBIDCNHWSW-UHFFFAOYSA-N 2-[1-(3,3-diphenylpropyl)piperidin-4-yl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC1)CCN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 ZSOZYBIDCNHWSW-UHFFFAOYSA-N 0.000 abstract 1
- XPSLLBXVEDRXQQ-UHFFFAOYSA-N 9-[4-[4-(3-oxo-1h-isoindol-2-yl)piperidin-1-yl]butyl]-n-propylfluorene-9-carboxamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCCC)CCCCN1CCC(N2C(C3=CC=CC=C3C2)=O)CC1 XPSLLBXVEDRXQQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16454799P | 1999-11-10 | 1999-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ508059A true NZ508059A (en) | 2002-11-26 |
Family
ID=22595001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ508059A NZ508059A (en) | 1999-11-10 | 2000-11-09 | Use of APO B secretion/MTP inhibitors to reduce intestinal fat absorption |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1099439A3 (pm) |
| JP (1) | JP2001172180A (pm) |
| KR (1) | KR20010051558A (pm) |
| AU (1) | AU6968700A (pm) |
| CA (1) | CA2324800A1 (pm) |
| CO (1) | CO5261534A1 (pm) |
| HU (1) | HUP0004461A3 (pm) |
| IL (1) | IL139448A0 (pm) |
| NZ (1) | NZ508059A (pm) |
| PE (1) | PE20010705A1 (pm) |
| ZA (1) | ZA200006419B (pm) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100717098B1 (ko) | 2002-02-28 | 2007-05-10 | 니뽄 다바코 산교 가부시키가이샤 | 에스테르 화합물 및 그 의약 용도 |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| WO2005021486A1 (ja) | 2003-08-29 | 2005-03-10 | Japan Tobacco Inc. | エステル誘導体及びその医薬用途 |
| US20060084636A1 (en) * | 2004-10-18 | 2006-04-20 | Maria Alemany | Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| WO2006046623A1 (ja) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
| CN101048180B (zh) * | 2004-10-25 | 2011-06-29 | 日本烟草产业株式会社 | 具有改善的溶解度和稳定性的固体制剂和用于制备所述制剂的方法 |
| JPWO2012124744A1 (ja) * | 2011-03-14 | 2014-07-24 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2091102C (en) * | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
| US5474993A (en) * | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
| EP0832069B1 (en) * | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| AU711279B2 (en) * | 1996-04-30 | 1999-10-07 | Pfizer Inc. | Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid (2-(2H-(1,2,4)triazol-3-ylmethyl)-1,2, 3,4-tetrahydro-isoquinolin-6-yl)-amide |
| KR100334567B1 (ko) * | 1996-11-27 | 2002-05-03 | 디. 제이. 우드, 스피겔 알렌 제이 | 아포 비-분비/엠티피 억제성 아미드 |
| US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| IL133201A0 (en) * | 1998-12-04 | 2001-03-19 | Pfizer Prod Inc | Lowering blood levels of lipoproten (a) |
-
2000
- 2000-10-31 CA CA002324800A patent/CA2324800A1/en not_active Abandoned
- 2000-11-02 AU AU69687/00A patent/AU6968700A/en not_active Abandoned
- 2000-11-02 IL IL13944800A patent/IL139448A0/xx unknown
- 2000-11-03 EP EP00309721A patent/EP1099439A3/en not_active Withdrawn
- 2000-11-08 ZA ZA200006419A patent/ZA200006419B/xx unknown
- 2000-11-09 NZ NZ508059A patent/NZ508059A/xx unknown
- 2000-11-09 HU HU0004461A patent/HUP0004461A3/hu unknown
- 2000-11-09 KR KR1020000066367A patent/KR20010051558A/ko not_active Ceased
- 2000-11-10 PE PE2000001207A patent/PE20010705A1/es not_active Application Discontinuation
- 2000-11-10 CO CO00085765A patent/CO5261534A1/es not_active Application Discontinuation
- 2000-11-10 JP JP2000342892A patent/JP2001172180A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU6968700A (en) | 2001-05-17 |
| EP1099439A2 (en) | 2001-05-16 |
| HUP0004461A2 (hu) | 2001-10-28 |
| CA2324800A1 (en) | 2001-05-10 |
| KR20010051558A (ko) | 2001-06-25 |
| ZA200006419B (en) | 2002-05-08 |
| JP2001172180A (ja) | 2001-06-26 |
| EP1099439A3 (en) | 2003-03-26 |
| CO5261534A1 (es) | 2003-03-31 |
| PE20010705A1 (es) | 2001-07-11 |
| HU0004461D0 (pm) | 2001-01-29 |
| HUP0004461A3 (en) | 2004-04-28 |
| IL139448A0 (en) | 2001-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2192394T3 (es) | Profarmacos de inhibidores de la bomba de protones. | |
| DK1064277T3 (da) | 2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner | |
| NO20003451L (no) | 2,3-substituerte indolforbindelser som cox-2 inhibitorer | |
| FI894066A0 (fi) | Depressionshaemmande n-substituerade nikotinamidfoereningar. | |
| DE3868301D1 (de) | 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung. | |
| HU229605B1 (en) | Substituted 4-(phenyl-n-alkyl)-piperidine derivatives, their use as modulators of dopamine neurotransmission and pharmaceutical compositions containing them | |
| SE9902648L (sv) | Kondenserade pyrrolkarboxanilider | |
| KR940021063A (ko) | 퀴놀론카르복실산 유도체, 이의 제조방법 및 용도 | |
| AR009212A1 (es) | Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen | |
| HU910706D0 (en) | Process for producing new n-(4-piperidinyl)-(dihydro-benzofurane- or dihydro-2h-benzopyrane)-carboxamide derivatives and pharmaceutical preparatives containing said compounds | |
| CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
| LU91196I2 (fr) | Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO). | |
| CO5080747A1 (es) | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p | |
| NZ508059A (en) | Use of APO B secretion/MTP inhibitors to reduce intestinal fat absorption | |
| FI925801A0 (fi) | Piperidyl-substituerade indoler | |
| DE68909855D1 (de) | 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisochinolin-Derivate, ihre Herstellung und ihre therapeutische Verwendung. | |
| ES2081810T3 (es) | Derivados de 4-fenil-4-(n-(2-fluorofenil)amido)-piperidina. | |
| CO5251424A1 (es) | Oxazinquinolonas utiles en el tratamiento de infecciones virales | |
| AR031808A1 (es) | 2-piridonas antimicrobianas, sus composiciones y usos | |
| AR015140A1 (es) | N-(3,4-dihidro-2h-piran-4-il)sulfonamidas, procedimiento para su preparacion, su utilizacion para la preparacion de un medicamento, un preparadofarmaceutico y medicamento | |
| NZ335975A (en) | Heterocyclic substituted pyrrolidine amide derivatives useful in treating respiratory diseases | |
| KR880006197A (ko) | 고혈압 및 울혈성 심장마비를 치료하기 위해 사용되는 약학적 조성물 | |
| ES2154561B1 (es) | Derivados de 2-fenilpiran-4-ona. | |
| FI980816L (fi) | Menetelmä alfa((heterosyklyylialkoksi)fenyyli)-omega-aryylialkaani-taialfa-((heterosyklyylioksi)fenyyli)-omega-aryylialkaaniyhdisteen valmistamiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |